COMPARATIVE EFFECTIVENESS IN DKD Cardiovascular-kidney-metabolic traits The choice between SGLT2 inhibitors and GLP-1 receptor agonists for managing DKD should be guided by a comprehensive assessment of an individuals cardiovascular-kidney-metabolic (CKM) health [83]
Back Habener, JF (Oct 1981) 'Recent advances in parathyroid hormone research', Clinical Biochemistry , 14/5, 223-29
We're also seeing the development of other novel compounds, like Survodutide (a dual GLP-1/GCG agonist), which explore different combinations of receptor targets
Should you shake or roll peptides after adding water
For a supplement to meaningfully boost GLP-1 levels, it would need to either dramatically increase GLP-1 production (far beyond what any food or supplement has been shown to do) or inhibit DPP-4 to slow GLP-1 breakdown
Its currently being studied in a phase 2 trial to test different doses